A Phase II, Open Label, Multiple Arm Study of Single Agent AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (NSCLC).

Trial Profile

A Phase II, Open Label, Multiple Arm Study of Single Agent AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (NSCLC).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 May 2017

At a glance

  • Drugs Alpelisib (Primary) ; Binimetinib (Primary) ; Capmatinib (Primary) ; Ceritinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 02 Aug 2016 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.
    • 02 Aug 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.
    • 21 Apr 2016 Patients will either receive 600 mg tablet or 400 mg capsule of Capmatinib.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top